The estimated Net Worth of Inc Pfizer Ventures (Us) Ll... is at least $2.65 millió dollars as of 16 March 2020. Inc Ll owns over 312,500 units of BioAtla stock worth over $2,652,277 and over the last 5 years Inc sold BCAB stock worth over $0.
Inc has made over 2 trades of the BioAtla stock since 2019, according to the Form 4 filled with the SEC. Most recently Inc bought 312,500 units of BCAB stock worth $5,000,000 on 16 March 2020.
The largest trade Inc's ever made was buying 312,500 units of BioAtla stock on 16 March 2020 worth over $5,000,000. On average, Inc trades about 120,833 units every 60 days since 2019. As of 16 March 2020 Inc still owns at least 1,481,719 units of BioAtla stock.
You can see the complete history of Inc Ll stock trades at the bottom of the page.
Inc's mailing address filed with the SEC is 235 E 42ND ST235 EAST 42ND STREET, , NEW YORKNEW YORK, NYNY, 1001710017.
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B... és Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BioAtla executives and other stock owners filed with the SEC include: